Jens Hansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jens Hansen has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Wolfgang Wurst
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
14 shared publications - Frank Schnütgen
Goethe University Frankfurt, Department of Medicine, Hematology/Oncology, Frankfurt/Main, Germany
7 shared publications Thomas Floss
6 shared publicationsHarald von Melchner
University Hospital Frankfurt, Goethe University 2 Department of Molecular Hematology D-60590 Frankfurt am Main , Germany
5 shared publicationsClaudia Seisenberger
Institute of Developmental Genetics, Helmholtz Zentrum München, Technische Universität München, Neuherberg, Germany
4 shared publicationsErwin Beck
University of Bayreuth
4 shared publications
Latest Publications
- Open Access
- 1 February 2021
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 14 (2)
Mutant non-coding RNA resource in mouse embryonic stem cells
Gene trapping is a high-throughput approach that has been used to introduce insertional mutations into the genome of mouse embryonic stem (ES) cells. It is performed with generic gene trap vectors that simultaneously mutate and report the expression of the endogenous gene at the site of insertion and provide a DNA sequence tag for the rapid identification of the disrupted gene. Large-scale international efforts assembled a gene trap library of 566,554 ES cell lines with single gene trap integrations distributed throughout the genome. Here, we re-investigated this unique library and identified mutations in 2202 non-coding RNA (ncRNA) genes, in addition to mutations in 12,078 distinct protein-coding genes. Moreover, we found certain types of gene trap vectors preferentially integrating into genes expressing specific long non-coding RNA (lncRNA) biotypes. Together with all other gene-trapped ES cell lines, lncRNA gene-trapped ES cell lines are readily available for functional in vitro and in vivo studies.
- 1 February 2021
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 14 (2)
Open AccessMutant non-coding RNA resource in mouse embryonic stem cells
Gene trapping is a high-throughput approach that has been used to introduce insertional mutations into the genome of mouse embryonic stem (ES) cells. It is performed with generic gene trap vectors that simultaneously mutate and report the expression of the endogenous gene at the site of insertion and provide a DNA sequence tag for the rapid identification of the disrupted gene. Large-scale international efforts assembled a gene trap library of 566,554 ES cell lines with single gene trap integrations distributed throughout the genome. Here, we re-investigated this unique library and identified mutations in 2202 non-coding RNA (ncRNA) genes, in addition to mutations in 12,078 distinct protein-coding genes. Moreover, we found certain types of gene trap vectors preferentially integrating into genes expressing specific long non-coding RNA (lncRNA) biotypes. Together with all other gene-trapped ES cell lines, lncRNA gene-trapped ES cell lines are readily available for functional in vitro and in vivo studies.
- 31 October 2013
- Published by Springer Nature in Nature Protocols
- Vol. 8 (12) , 2355-2379
Generation of targeted mouse mutants by embryo microinjection of TALEN mRNA
Genetically engineered mice are instrumental for the analysis of mammalian gene function in health and disease. As classical gene targeting, which is performed in embryonic stem (ES) cell cultures and generates chimeric mice, is a time-consuming and labor-intensive procedure, we recently used transcription activator-like (TAL) effector nucleases (TALENs) for mutagenesis of the mouse genome directly in one-cell embryos. Here we describe a stepwise protocol for the generation of knock-in and knockout mice, including the selection of TALEN-binding sites, the design and construction of TALEN coding regions and of mutagenic oligodeoxynucleotides (ODNs) and targeting vectors, mRNA production, embryo microinjection and the identification of modified alleles in founder mutants and their progeny. After a setup time of 2-3 weeks of hands-on work for TALEN construction, investigators can obtain first founder mutants for genes of choice within 7 weeks after embryo microinjections.
- 31 October 2013
- Published by Springer Nature in Nature Protocols
- Vol. 8 (12) , 2355-2379
Generation of targeted mouse mutants by embryo microinjection of TALEN mRNA
Genetically engineered mice are instrumental for the analysis of mammalian gene function in health and disease. As classical gene targeting, which is performed in embryonic stem (ES) cell cultures and generates chimeric mice, is a time-consuming and labor-intensive procedure, we recently used transcription activator-like (TAL) effector nucleases (TALENs) for mutagenesis of the mouse genome directly in one-cell embryos. Here we describe a stepwise protocol for the generation of knock-in and knockout mice, including the selection of TALEN-binding sites, the design and construction of TALEN coding regions and of mutagenic oligodeoxynucleotides (ODNs) and targeting vectors, mRNA production, embryo microinjection and the identification of modified alleles in founder mutants and their progeny. After a setup time of 2-3 weeks of hands-on work for TALEN construction, investigators can obtain first founder mutants for genes of choice within 7 weeks after embryo microinjections.
- Open Access
- 20 February 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (10) , 3782-3787
Direct production of mouse disease models by embryo microinjection of TALENs and oligodeoxynucleotides
The study of genetic disease mechanisms relies mostly on targeted mouse mutants that are derived from engineered embryonic stem (ES) cells. Nevertheless, the establishment of mutant ES cells is laborious and time-consuming, restricting the study of the increasing number of human disease mutations discovered by high-throughput genomic analysis. Here, we present an advanced approach for the production of mouse disease models by microinjection of transcription activator-like effector nucleases (TALENs) and synthetic oligodeoxynucleotides into one-cell embryos. Within 2 d of embryo injection, we created and correctedchocolatemissense mutations in the small GTPase RAB38; a regulator of intracellular vesicle trafficking and phenotypic model of Hermansky-Pudlak syndrome. Because ES cell cultures and targeting vectors are not required, this technology enables instant germline modifications, making heterozygous mutants available within 18 wk. The key features of direct mutagenesis by TALENs and oligodeoxynucleotides, minimal effort and high speed, catalyze the generation of future in vivo models for the study of human disease mechanisms and interventions.
- 20 February 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (10) , 3782-3787
Open AccessDirect production of mouse disease models by embryo microinjection of TALENs and oligodeoxynucleotides
The study of genetic disease mechanisms relies mostly on targeted mouse mutants that are derived from engineered embryonic stem (ES) cells. Nevertheless, the establishment of mutant ES cells is laborious and time-consuming, restricting the study of the increasing number of human disease mutations discovered by high-throughput genomic analysis. Here, we present an advanced approach for the production of mouse disease models by microinjection of transcription activator-like effector nucleases (TALENs) and synthetic oligodeoxynucleotides into one-cell embryos. Within 2 d of embryo injection, we created and correctedchocolatemissense mutations in the small GTPase RAB38; a regulator of intracellular vesicle trafficking and phenotypic model of Hermansky-Pudlak syndrome. Because ES cell cultures and targeting vectors are not required, this technology enables instant germline modifications, making heterozygous mutants available within 18 wk. The key features of direct mutagenesis by TALENs and oligodeoxynucleotides, minimal effort and high speed, catalyze the generation of future in vivo models for the study of human disease mechanisms and interventions.
- Open Access
- 12 September 2012
- Published by Springer Nature in Mammalian Genome
- Vol. 23 (9-10) , 580-586
The mammalian gene function resource: the international knockout mouse consortium
In 2007, the International Knockout Mouse Consortium (IKMC) made the ambitious promise to generate mutations in virtually every protein-coding gene of the mouse genome in a concerted worldwide action. Now, 5 years later, the IKMC members have developed high-throughput gene trapping and, in particular, gene-targeting pipelines and generated more than 17,400 mutant murine embryonic stem (ES) cell clones and more than 1,700 mutant mouse strains, most of them conditional. A common IKMC web portal (www.knockoutmouse.org) has been established, allowing easy access to this unparalleled biological resource. The IKMC materials considerably enhance functional gene annotation of the mammalian genome and will have a major impact on future biomedical research.
- 12 September 2012
- Published by Springer Nature in Mammalian Genome
- Vol. 23 (9-10) , 580-586
Open AccessThe mammalian gene function resource: the international knockout mouse consortium
In 2007, the International Knockout Mouse Consortium (IKMC) made the ambitious promise to generate mutations in virtually every protein-coding gene of the mouse genome in a concerted worldwide action. Now, 5 years later, the IKMC members have developed high-throughput gene trapping and, in particular, gene-targeting pipelines and generated more than 17,400 mutant murine embryonic stem (ES) cell clones and more than 1,700 mutant mouse strains, most of them conditional. A common IKMC web portal (www.knockoutmouse.org) has been established, allowing easy access to this unparalleled biological resource. The IKMC materials considerably enhance functional gene annotation of the mammalian genome and will have a major impact on future biomedical research.
- Open Access
- 17 May 2012
- Published by Springer Nature in BMC Medical Genetics
- Vol. 13 (1) , 35
Computational identification and experimental validation of microRNAs binding to the Alzheimer-related gene ADAM10
Background: MicroRNAs (miRNAs) are post-transcriptional regulators involved in numerous biological processes including the pathogenesis of Alzheimer’s disease (AD). A key gene of AD,ADAM10, controls the proteolytic processing ofAPPand the formation of the amyloid plaques and is known to be regulated by miRNA in hepatic cancer cell lines. To predict miRNAs regulatingADAM10expression concerning AD, we developed a computational approach.Methods: MiRNA binding sites in the humanADAM103' untranslated region were predicted using the RNA22, RNAhybrid and miRanda programs and ranked by specific selection criteria with respect to AD such as differential regulation in AD patients and tissue-specific expression. Furthermore, target genes ofmiR-103,miR-107andmiR-1306were derived from six publicly available miRNA target site prediction databases. Only target genes predicted in at least four out of six databases in the case ofmiR-103andmiR-107were compared to genes listed in the AlzGene database including genes possibly involved in AD. In addition, the target genes were used for Gene Ontology analysis and literature mining. Finally, we used a luciferase assay to verify the potential effect of these three miRNAs onADAM103'UTR in SH-SY5Y cells.Results: Eleven miRNAs were selected, which have evolutionary conserved binding sites. Three of them (miR-103,miR-107,miR-1306) were further analysed as they are linked to AD and most strictly conserved between different species. Predicted target genes ofmiR-103(p-value = 0.0065) andmiR-107(p-value = 0.0009) showed significant overlap with the AlzGene database except formiR-1306. Interactions betweenmiR-103andmiR-107to genes were revealed playing a role in processes leading to AD.ADAM10expression in the reporter assay was reduced bymiR-1306(28%),miR-103(45%) andmiR-107(52%).Conclusions: Our approach shows the requirement of incorporating specific, disease-associated selection criteria into the prediction process to reduce the amount of false positive predictions. In summary, our method identified three miRNAs strongly suggested to be involved in AD, which possibly regulateADAM10expression and hence offer possibilities for the development of therapeutic treatments of AD.
- 17 May 2012
- Published by Springer Nature in BMC Medical Genetics
- Vol. 13 (1) , 35
Open AccessComputational identification and experimental validation of microRNAs binding to the Alzheimer-related gene ADAM10
Background: MicroRNAs (miRNAs) are post-transcriptional regulators involved in numerous biological processes including the pathogenesis of Alzheimer’s disease (AD). A key gene of AD,ADAM10, controls the proteolytic processing ofAPPand the formation of the amyloid plaques and is known to be regulated by miRNA in hepatic cancer cell lines. To predict miRNAs regulatingADAM10expression concerning AD, we developed a computational approach.Methods: MiRNA binding sites in the humanADAM103' untranslated region were predicted using the RNA22, RNAhybrid and miRanda programs and ranked by specific selection criteria with respect to AD such as differential regulation in AD patients and tissue-specific expression. Furthermore, target genes ofmiR-103,miR-107andmiR-1306were derived from six publicly available miRNA target site prediction databases. Only target genes predicted in at least four out of six databases in the case ofmiR-103andmiR-107were compared to genes listed in the AlzGene database including genes possibly involved in AD. In addition, the target genes were used for Gene Ontology analysis and literature mining. Finally, we used a luciferase assay to verify the potential effect of these three miRNAs onADAM103'UTR in SH-SY5Y cells.Results: Eleven miRNAs were selected, which have evolutionary conserved binding sites. Three of them (miR-103,miR-107,miR-1306) were further analysed as they are linked to AD and most strictly conserved between different species. Predicted target genes ofmiR-103(p-value = 0.0065) andmiR-107(p-value = 0.0009) showed significant overlap with the AlzGene database except formiR-1306. Interactions betweenmiR-103andmiR-107to genes were revealed playing a role in processes leading to AD.ADAM10expression in the reporter assay was reduced bymiR-1306(28%),miR-103(45%) andmiR-107(52%).Conclusions: Our approach shows the requirement of incorporating specific, disease-associated selection criteria into the prediction process to reduce the amount of false positive predictions. In summary, our method identified three miRNAs strongly suggested to be involved in AD, which possibly regulateADAM10expression and hence offer possibilities for the development of therapeutic treatments of AD.
- Open Access
- 18 April 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (4) , e35035
MAPK Signaling Determines Anxiety in the Juvenile Mouse Brain but Depression-Like Behavior in Adults
MAP kinase signaling has been implicated in brain development, long-term memory, and the response to antidepressants. Inducible Braf knockout mice, which exhibit protein depletion in principle forebrain neurons, enabled us to unravel a new role of neuronal MAPK signaling for emotional behavior. Braf mice that were induced during adulthood showed normal anxiety but increased depression-like behavior, in accordance with pharmacological findings. In contrast, the inducible or constitutive inactivation of Braf in the juvenile brain leads to normal depression-like behavior but decreased anxiety in adults. In juvenile, constitutive mutants we found no alteration of GABAergic neurotransmission but reduced neuronal arborization in the dentate gyrus. Analysis of gene expression in the hippocampus revealed nine downregulated MAPK target genes that represent candidates to cause the mutant phenotype. Our results reveal the differential function of MAPK signaling in juvenile and adult life phases and emphasize the early postnatal period as critical for the determination of anxiety in adults. Moreover, these results validate inducible gene inactivation as a new valuable approach, allowing it to discriminate between gene function in the adult and the developing postnatal brain.
- 18 April 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (4) , e35035
Open AccessMAPK Signaling Determines Anxiety in the Juvenile Mouse Brain but Depression-Like Behavior in Adults
MAP kinase signaling has been implicated in brain development, long-term memory, and the response to antidepressants. Inducible Braf knockout mice, which exhibit protein depletion in principle forebrain neurons, enabled us to unravel a new role of neuronal MAPK signaling for emotional behavior. Braf mice that were induced during adulthood showed normal anxiety but increased depression-like behavior, in accordance with pharmacological findings. In contrast, the inducible or constitutive inactivation of Braf in the juvenile brain leads to normal depression-like behavior but decreased anxiety in adults. In juvenile, constitutive mutants we found no alteration of GABAergic neurotransmission but reduced neuronal arborization in the dentate gyrus. Analysis of gene expression in the hippocampus revealed nine downregulated MAPK target genes that represent candidates to cause the mutant phenotype. Our results reveal the differential function of MAPK signaling in juvenile and adult life phases and emphasize the early postnatal period as critical for the determination of anxiety in adults. Moreover, these results validate inducible gene inactivation as a new valuable approach, allowing it to discriminate between gene function in the adult and the developing postnatal brain.
- 28 January 2011
- Published by Springer Nature in Nature Methods
- Vol. 8 (2) , 103-104
Resources for proteomics in mouse embryonic stem cells.
- 28 January 2011
- Published by Springer Nature in Nature Methods
- Vol. 8 (2) , 103-104
Resources for proteomics in mouse embryonic stem cells.
- Open Access
- 1 January 2011
- Published by Wiley in International Journal of Alzheimer's Disease
- Vol. 2011 (1) , 154325
Bioinformatics Identification of Modules of Transcription Factor Binding Sites in Alzheimer′s Disease‐Related Genes by In Silico Promoter Analysis and Microarrays
The molecular mechanisms and genetic risk factors underlying Alzheimer′s disease (AD) pathogenesis are only partly understood. To identify new factors, which may contribute to AD, different approaches are taken including proteomics, genetics, and functional genomics. Here, we used a bioinformatics approach and found that distinct AD‐related genes share modules of transcription factor binding sites, suggesting a transcriptional coregulation. To detect additional coregulated genes, which may potentially contribute to AD, we established a new bioinformatics workflow with known multivariate methods like support vector machines, biclustering, and predicted transcription factor binding site modules by using in silico analysis and over 400 expression arrays from human and mouse. Two significant modules are composed of three transcription factor families: CTCF, SP1F, and EGRF/ZBPF, which are conserved between human and mouse APP promoter sequences. The specific combination of in silico promoter and multivariate analysis can identify regulation mechanisms of genes involved in multifactorial diseases.
- 1 January 2011
- Published by Wiley in International Journal of Alzheimer's Disease
- Vol. 2011 (1) , 154325
Open AccessBioinformatics Identification of Modules of Transcription Factor Binding Sites in Alzheimer′s Disease‐Related Genes by In Silico Promoter Analysis and Microarrays
The molecular mechanisms and genetic risk factors underlying Alzheimer′s disease (AD) pathogenesis are only partly understood. To identify new factors, which may contribute to AD, different approaches are taken including proteomics, genetics, and functional genomics. Here, we used a bioinformatics approach and found that distinct AD‐related genes share modules of transcription factor binding sites, suggesting a transcriptional coregulation. To detect additional coregulated genes, which may potentially contribute to AD, we established a new bioinformatics workflow with known multivariate methods like support vector machines, biclustering, and predicted transcription factor binding site modules by using in silico analysis and over 400 expression arrays from human and mouse. Two significant modules are composed of three transcription factor families: CTCF, SP1F, and EGRF/ZBPF, which are conserved between human and mouse APP promoter sequences. The specific combination of in silico promoter and multivariate analysis can identify regulation mechanisms of genes involved in multifactorial diseases.
- Open Access
- 6 October 2010
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 39 (Database) , D849-D855
The IKMC web portal: a central point of entry to data and resources from the International Knockout Mouse Consortium
The International Knockout Mouse Consortium (IKMC) aims to mutate all protein-coding genes in the mouse using a combination of gene targeting and gene trapping in mouse embryonic stem (ES) cells and to make the generated resources readily available to the research community. The IKMC database and web portal ( www.knockoutmouse.org ) serves as the central public web site for IKMC data and facilitates the coordination and prioritization of work within the consortium. Researchers can access up-to-date information on IKMC knockout vectors, ES cells and mice for specific genes, and follow links to the respective repositories from which corresponding IKMC products can be ordered. Researchers can also use the web site to nominate genes for targeting, or to indicate that targeting of a gene should receive high priority. The IKMC database provides data to, and features extensive interconnections with, other community databases.
- 6 October 2010
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 39 (Database) , D849-D855
Open AccessThe IKMC web portal: a central point of entry to data and resources from the International Knockout Mouse Consortium
The International Knockout Mouse Consortium (IKMC) aims to mutate all protein-coding genes in the mouse using a combination of gene targeting and gene trapping in mouse embryonic stem (ES) cells and to make the generated resources readily available to the research community. The IKMC database and web portal ( www.knockoutmouse.org ) serves as the central public web site for IKMC data and facilitates the coordination and prioritization of work within the consortium. Researchers can access up-to-date information on IKMC knockout vectors, ES cells and mice for specific genes, and follow links to the respective repositories from which corresponding IKMC products can be ordered. Researchers can also use the web site to nominate genes for targeting, or to indicate that targeting of a gene should receive high priority. The IKMC database provides data to, and features extensive interconnections with, other community databases.
- Open Access
- 5 February 2010
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 38 (9) , e106
Efficient conditional and promoter-specific in vivo expression of cDNAs of choice by taking advantage of recombinase-mediated cassette exchange using FlEx gene traps
Recombinase-mediated cassette exchange (RMCE) exploits the possibility to unidirectionally exchange any genetic material flanked by heterotypic recombinase recognition sites (RRS) with target sites in the genome. Due to a limited number of available pre-fabricated target sites, RMCE in mouse embryonic stem (ES) cells has not been tapped to its full potential to date. Here, we introduce a universal system, which allows the targeted insertion of any given transcriptional unit into 85 742 previously annotated retroviral conditional gene trap insertions, representing 7013 independent genes in mouse ES cells, by RMCE. This system can be used to express any given cDNA under the control of endogenous trapped promoters in vivo, as well as for the generation of transposon ‘launch pads’ for chromosomal region-specific ‘Sleeping Beauty’ insertional mutagenesis. Moreover, transcription of the gene-of-interest is only activated upon Cre-recombinase activity, a feature that adds conditionality to this expression system, which is demonstrated in vivo. The use of the RMCE system presented in this work requires one single-cloning step followed by one overnight gateway clonase reaction and subsequent cassette exchange in ES cells with efficiencies of 40% in average.
- 5 February 2010
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 38 (9) , e106
Open AccessEfficient conditional and promoter-specific in vivo expression of cDNAs of choice by taking advantage of recombinase-mediated cassette exchange using FlEx gene traps
Recombinase-mediated cassette exchange (RMCE) exploits the possibility to unidirectionally exchange any genetic material flanked by heterotypic recombinase recognition sites (RRS) with target sites in the genome. Due to a limited number of available pre-fabricated target sites, RMCE in mouse embryonic stem (ES) cells has not been tapped to its full potential to date. Here, we introduce a universal system, which allows the targeted insertion of any given transcriptional unit into 85 742 previously annotated retroviral conditional gene trap insertions, representing 7013 independent genes in mouse ES cells, by RMCE. This system can be used to express any given cDNA under the control of endogenous trapped promoters in vivo, as well as for the generation of transposon ‘launch pads’ for chromosomal region-specific ‘Sleeping Beauty’ insertional mutagenesis. Moreover, transcription of the gene-of-interest is only activated upon Cre-recombinase activity, a feature that adds conditionality to this expression system, which is demonstrated in vivo. The use of the RMCE system presented in this work requires one single-cloning step followed by one overnight gateway clonase reaction and subsequent cassette exchange in ES cells with efficiencies of 40% in average.